178 related articles for article (PubMed ID: 2183874)
1. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
3. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG
Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
10. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
12. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita).
Filippich LJ; Charles BG; Sutton RH; Bucher AM
Aust Vet J; 2004 Jun; 82(6):366-9. PubMed ID: 15267096
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Shea TC; Flaherty M; Elias A; Eder JP; Antman K; Begg C; Schnipper L; Frei E; Henner WD
J Clin Oncol; 1989 May; 7(5):651-61. PubMed ID: 2651580
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of carboplatin after intraperitoneal administration.
Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG
Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734
[TBL] [Abstract][Full Text] [Related]
19. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of carboplatin in a patient under hemodialysis].
Kurata H; Yoshiya N; Ikarashi H; Kaneko T; Kodama S; Tanaka K; Suzuki K; Yoshizawa H; Cho T; Suzuki E
Gan To Kagaku Ryoho; 1994 Mar; 21(4):547-50. PubMed ID: 8129398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
